Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25- dihydroxyvitamin D (calcitriol) and EB1089

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 3, 1999, Pages 241-248

  Lokeshwar, Bal L ^a   Schwartz, Gary G ^a   Selzer, Marie G ^a   Burnstein, Kerry L ^c   Zhuang, Sen Hong ^c   Block, Norman L ^a   Binderup, Lise ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b LEO PHARMA A S   (Denmark)

^c Univ of Miami School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; SEOCALCITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; HYPERCALCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MALE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CACHEXIA; CALCITRIOL; CALCIUM; CELL DIFFERENTIATION; CELL DIVISION; DISEASE MODELS, ANIMAL; HUMANS; HYPERCALCEMIA; INJECTIONS, INTRAPERITONEAL; LUNG NEOPLASMS; MALE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED; VEHICLES; WEIGHT GAIN; WEIGHT LOSS;

EID: 0032963132     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J Clin, 48: 6-29, 1998.
2. Kirby, R. S. Recent advances in the medical management of prostate cancer. Br. J. Clin. Practice, 50: 88-93, 1996.
3. Logothetis, C. J. Management of androgen-independent prostate carcinoma. In: H. Lepor and R. K. Lawson (eds.), Prostate Diseases, pp. 364-367. Philadelphia: WB Saunders, 1993.
4. Kirby, R. S., Christmas, T. J., and Brawer, M. K. Prostate Cancer. London: Mosby, 1996.
5. Campbell, M. J., and Koeffler, H. P. Toward the intervention of cancer with vitamin D compounds. J. Natl. Cancer Inst., 89: 182-183, 1997.
6. Studzinski, G. P., McLane, J. A., and Uskokovic, M. R. Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Crit. Rev. Eukaryotic Gene Express., 3: 279-312, 1993.
7. Bikle, D. D. Clinical Counterpoint. Vitamin D: new actions, new analogues, new therapeutic potential. Endocr. Rev., 13: 719-764, 1992.
8. Schwartz, G. G., and Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis) Anticancer Res., 10: 1307-1311, 1990.
9. Hanchette, C. L., and Schwartz, G. G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer (Phila.), 70: 2861-2869, 1992.
10. Schwartz, G. G. Prostate cancer and the vitamin D hypothesis. In: M. F. Holick and E. Jung (eds.), Biological Effects of Light 1995, pp. 309-316. Berlin: Walter de Gruyter, 1996.
11. 3. Cancer Res., 52: 515-520, 1992.
12. Skowronski, R. J., Peehl, D. M., and Feldman, D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines Endocrinology, 132: 1952-1960, 1993.
13. Schwartz, G. G., Oeler, T. A., Uskokovic, M. R., and Bahnson, R. R. Human prostate cancer cell lines: inhibition of proliferation by vitamin D analogs. Anticancer Res., 14: 1077-1081, 1994.
14. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1: 997-1003, 1995.
15. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
16. Peehl, D. M., Skowronski, R. J., and Leung, G. K., Wong, S. T., Stamey, T. A, and Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
17. Schwartz, G. G., Wang, M-H., Zhang, M., Singh, R. J., and Siegal, G. P. 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomark. Prev., 6: 727-732, 1997.
18. Konety, B. R., Schwartz, G. G., Acierno, J. S., Jr., Becich, M. J., and Getzenberg, R. H. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ., 7: 1563-1570, 1996.
19. Gross, C., Peehl, D., and Feldman, D. Prostate cancer and vitamin D. In: Feldman (ed)., Vitamin D. New York: Academic Press, 1997.
20. Schwartz, G. G., Whitlatch, T. W., Chen, T. C., Lokeshwar, B. L., and Holick, M. F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomark. Prev., 7: 391-395, 1998.
21. Brown, A. J. Vitamin D analogues. Am. J. Kidney Dis., 32 (Suppl. 2): S25-S39, 1998.
22. Skowronski, R. J., Peehl, D. M., and Feldman, D. Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology, 136: 20-26, 1995.
23. Haq, M., Kremer, R., Goltzman, D., and Rabbani, S. A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin. Invest., 91: 2416-2422, 1993.
24. Isaacs, J. T., Isaacs, W. B., Feitz, W. F., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
25. Schwartz, G. G., Hill, C. C., Oeler, T. A., Becich, M. J., and Bahnson, R. R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology, 46: 365-369, 1995.
26. Zhuang, S-H., Schwartz, G. G., Cameron, D., and Burnstein, K. L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinol., 126: 83-90, 1997.
27. Wecksler, W. R., and Norman, A. W. An hydroxylapatite batch assay for the quanlitation of 1α,25-dihydroxyvitamin D3-receptor complexes. Anal. Biochem., 92: 314-323, 1979.
28. Cheskis, B., and Freedman, L. P. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol. Cell. Biol., 14: 3329-3338, 1994.
29. Noda, M., Vogel, R. L., Craig, A. M., Prahl, J., DeLuca, H. F., and Denhardt, D. T. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. USA, 87: 9995-9999, 1990.
30. Luckow, B., and Schutz, G. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res., 15: 5490, 1987.
31. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
32. Gorman, C. M., Moffat, L. F., and Howard, B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol., 2: 1044-1051, 1982.
33. Getzenberg, R. H., Light, B. W., Lapco, P. E., Konety, B. R., Nangia, A. K., Acierno, J. S., Dhir, R., Shurin, Z., Day, R. S., Trump, D. L., and Johnson, C. S. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology, 50: 999-1006, 1997.
34. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3: 65-71, 1992.
35. Weidner, N., Carroll, P. R., Flax, J., Blumenfield, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143: 401-407, 1993.
36. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethlybenz[α]anthracene. Anticancer Drugs, 2: 475-480, 1991.
37. Shokravi, M. T., Marcus, D. M., Alroy, J., Egan, K., Saornil, M. A., and Albert, D. M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastomas. Invest. Ophthalmol., 36: 83-87, 1995.
38. Berger, U., Wilson, P., McClelland, R. A., Colslon, K., Haussler, M. R., Pike, J. W., and Coombes, R. C. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J. Clin. Endocrinol. Metab., 67: 607-613, 1988.
39. Revelli, A., Massobrio, M., and Tesarik, J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr. Rev., 19: 3-17, 1998.
40. Dusso, A. S., and Brown, A. J. Mechanism of vitamin D action and its regulation. Am. J. Kidney Dis., 32 (Suppl. 2): S13-S24, 1998.
41. Nemere, I., Schwartz, Z., Pedrozo, H., Sylvia, V. L., Dean, D. D., and Boyan, B. D. Identification of a membrane receptor for 1,25-dihydroxy vitamin D3 which mediates rapid activation of protein kinase C. J. Bone Miner. Res., 13: 1353-1359, 1998.
42. 2 D3: past, present and future. J. Bone Miner. Res., 13: 1360-1369, 1998.
43. Waltregny, D., and Castronovo, V. Recent advances in prostate cancer metastasis. Tumori, 82: 193-204, 1996.
44. Breslow, N., Chan, C. W., Dhom, G., Drury, R. A., Franks, L. M., Gellei, B., Lee, Y. S., Lundberg, S., Sparke, B., Sternby, N. H., and Tulinius, H. Latent carcinoma of the prostate at autopsy in seven areas. Int. J. Cancer, 20: 680-688, 1997.
45. Corder, E. H., Guess, H. A., Hulka, B. S., Friedman, G. D., Sadler, M., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogelman, J. H., and Orentreich, N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomark. Prev., 2: 467-472, 1993.
46. Gann, P. H., Ma, J., Hennekens, C. H., Hollis, B. W., Haddad, J. G., and Stampfer, M. J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomark. Prev., 5: 121-126, 1996.
47. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L., and Bell, D. A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108-4110, 1996.
48. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166-170, 1997.
49. Kelsey, S. M., Newland, A. C., Cunningham, J., Makin, H. K. J., Coldwell, R. D., Mills, M. E., and Grant, I. R. Sustained hematological response to high-dose alfacalcidol in patients with myelodysolastic syndromes. Lancet, 340: 316-317, 1992.
50. Mortensen, J. T., Brinck, P., and Binderup, L. Toxicity of vitamin D analogues in rats fed diets with standard or low calcium contents. Pharmacol. Toxicol., 72: 124-127, 1993.
51. Osborn, J. L., Schwartz, G. G., Bahnson, R., Smith, D. C., and Trump, D. L. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1: 195-198, 1995.
52. Gross, C., Stamey, T., Hancock, S., and Feldman, D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol., 159: 2035-2040, 1998.